Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...

Blue Trust Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 46.3% during the third quarter, ...

OLD National Bancorp IN lessened its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.0% during the 3rd ...